Design for manufacture of an innovative Extra Corporeal Membrane Oxygenator

创新型体外膜氧合器的制造设计

• 批准号: 102138
• 金额: $ 154.54万
• 依托单位: HAEMAIR LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102138
• 关键词: Design; manufacture; innovative; Extra; Corporeal

Respiratory problems cost the NHS over £2,500 million/annum. The project aims to deliver safe effective Extracorporeal Membrane Oxygenation with reduced risk of blood clots that will improve lives and reduce these costs. Current alternatives have a propensity to cause blood clots and consequently require high levels of anticoagulation. This anticoagulation introduces a risk of haemorrhage and striking a balance between thrombosis and haemorrhage restricts use to a small number of expensive specialist centres. The initial focus is on post-operative support for cardiopulmonary patients to improve recovery rates and reduce hospital stays. Future developments foresee application to a wide range of conditions including drug-free treatment for aggressive ‘flu pandemics and, in the longer term, support for people suffering chronic lung diseases. It is anticipated that over 90% of production from facilities in South Wales will be exported.

呼吸系统问题每年给 NHS 造成超过 25 亿英镑的损失。该项目旨在提供安全有效的体外膜氧合，降低血栓风险，从而改善生活并降低这些成本。目前的替代品有引起血栓的倾向，因此需要高水平的抗凝治疗。这种抗凝治疗会带来出血的风险，并且在血栓形成和出血之间取得平衡限制了少数昂贵的专科中心的使用。最初的重点是为心肺患者提供术后支持，以提高康复率并减少住院时间。未来的发展预计将应用于广泛的疾病领域，包括针对侵袭性流感大流行的无药物治疗，以及从长远来看，为患有慢性肺部疾病的人们提供支持。预计南威尔士工厂 90% 以上的产品将用于出口。